KANK4

Summary

KANK4 (KN motif and ankyrin repeat domains 4, HGNC:27263) is a protein-coding gene on chromosome 1p31.3, encoding KN motif and ankyrin repeat domain-containing protein 4 (Q5T7N3). May be involved in the control of cytoskeleton formation by regulating actin polymerization.

Predicted to be involved in negative regulation of actin filament polymerization. Located in cytosol and microtubule cytoskeleton.

Source: NCBI Gene 163782 — RefSeq curated summary.

At a glance

• Gene–disease (curated): nephrotic syndrome (Moderate, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 419 total
• MANE Select transcript: NM_181712

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:27263
Approved symbol	KANK4
Name	KN motif and ankyrin repeat domains 4
Location	1p31.3
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0172
Ensembl gene	ENSG00000132854
Ensembl biotype	protein_coding
OMIM	614612
Entrez	163782

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 10 protein_coding

ENST00000317477, ENST00000354381, ENST00000371150, ENST00000371153, ENST00000880983, ENST00000880984, ENST00000880985, ENST00000880986, ENST00000911278, ENST00000959619

RefSeq mRNA: 2 — MANE Select: NM_181712 NM_001320269, NM_181712

CCDS: CCDS620, CCDS81334

Canonical transcript exons

ENST00000371153 — 10 exons

Exon	Start	End
ENSE00001348606	62247472	62247672
ENSE00001418170	62319106	62319434
ENSE00001421106	62281549	62281634
ENSE00001424755	62273204	62275087
ENSE00001615716	62266732	62266819
ENSE00001663340	62263092	62263311
ENSE00001783576	62271478	62271589
ENSE00001801128	62268287	62268505
ENSE00003680432	62253067	62253209
ENSE00003847626	62236165	62238381

Expression profiles

Bgee: expression breadth ubiquitous, 198 present calls, max score 98.20.

FANTOM5 (CAGE): breadth broad, TPM avg 1.6644 / max 157.5272, expressed in 426 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
12627	0.8594	306
12624	0.4215	153
12625	0.2061	90
12626	0.1594	72
12623	0.0181	5

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
trigeminal ganglion	UBERON:0001675	98.20	gold quality
dorsal root ganglion	UBERON:0000044	97.90	gold quality
substantia nigra pars compacta	UBERON:0001965	94.93	gold quality
substantia nigra pars reticulata	UBERON:0001966	94.84	gold quality
inferior vagus X ganglion	UBERON:0005363	93.58	gold quality
sural nerve	UBERON:0015488	92.32	gold quality
pons	UBERON:0000988	92.14	gold quality
buccal mucosa cell	CL:0002336	89.73	gold quality
parotid gland	UBERON:0001831	88.86	gold quality
superior vestibular nucleus	UBERON:0007227	88.20	gold quality
medulla oblongata	UBERON:0001896	88.09	gold quality
tibial nerve	UBERON:0001323	87.10	gold quality
placenta	UBERON:0001987	85.53	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.26	gold quality
subthalamic nucleus	UBERON:0001906	84.30	gold quality
body of pancreas	UBERON:0001150	82.13	gold quality
midbrain	UBERON:0001891	81.64	gold quality
ventral tegmental area	UBERON:0002691	81.45	gold quality
substantia nigra	UBERON:0002038	80.93	gold quality
spinal cord	UBERON:0002240	80.07	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	79.37	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.22	gold quality
pylorus	UBERON:0001166	76.81	gold quality
dorsal plus ventral thalamus	UBERON:0001897	76.07	gold quality
pancreas	UBERON:0001264	76.02	gold quality
globus pallidus	UBERON:0001875	75.70	gold quality
medial globus pallidus	UBERON:0002477	75.48	gold quality
mammary gland	UBERON:0001911	75.24	gold quality
thoracic mammary gland	UBERON:0005200	75.17	gold quality
endothelial cell	CL:0000115	74.27	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.42

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

84 targeting KANK4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-6744-5P	99.93	66.82	748
HSA-MIR-3682-5P	99.93	67.97	1163
HSA-MIR-613	99.91	71.50	1710
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-137-3P	99.87	74.74	2401
HSA-MIR-221-3P	99.86	71.56	1329
HSA-MIR-222-3P	99.86	71.35	1337
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-448	99.79	72.37	2103
HSA-MIR-2052	99.79	69.37	2031
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-3680-3P	99.75	72.51	3095

Literature-anchored findings (GeneRIF, showing 4)

• identified recessive mutations in kidney ankyrin repeat-containing protein 1 (KANK1), KANK2, and KANK4 in individuals with nephrotic syndrome. (PMID:25961457)
• biomarkers suitable for the assessment of chronological ageing were identified, and extrapolated to the context of photo-damaged skin. In particular, KANK4, ACAN, Col XI alpha1, and PSG1, were expressed at an increased level in both chronologically-aged and photo-damaged skin. (PMID:29913199)
• DHCR7 promotes lymph node metastasis in cervical cancer through cholesterol reprogramming-mediated activation of the KANK4/PI3K/AKT axis and VEGF-C secretion. (PMID:38211648)
• Exclusive expression of KANK4 promotes myofibroblast mobility in keloid tissues. (PMID:38622256)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	kank4	ENSDARG00000059473
mus_musculus	Kank4	ENSMUSG00000035407
rattus_norvegicus	Kank4	ENSRNOG00000007779
drosophila_melanogaster	Kank	FBGN0027596
caenorhabditis_elegans		WBGENE00006882

Paralogs (3): KANK1 (ENSG00000107104), KANK3 (ENSG00000186994), KANK2 (ENSG00000197256)

Protein

Protein identifiers

KN motif and ankyrin repeat domain-containing protein 4 — Q5T7N3 (reviewed: Q5T7N3)

Alternative names: Ankyrin repeat domain-containing protein 38

All UniProt accessions (3): B1ALP5, B1ALP6, Q5T7N3

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in the control of cytoskeleton formation by regulating actin polymerization.

Subcellular location. Cytoplasm.

Tissue specificity. Strongly expressed in colon, liver, lung, skeletal muscle and kidney.

Isoforms (2)

UniProt ID	Names	Canonical?
Q5T7N3-1	1	yes
Q5T7N3-2	2

RefSeq proteins (2): NP_001307198, NP_859063* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002110	Ankyrin_rpt	Repeat
IPR021939	KN_motif	Conserved_site
IPR036770	Ankyrin_rpt-contain_sf	Homologous_superfamily
IPR047184	KANK1-4	Family

Pfam: PF12075, PF12796

UniProt features (31 total): region of interest 7, sequence variant 7, compositionally biased region 6, repeat 5, splice variant 2, sequence conflict 2, chain 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5T7N3-F1	57.17	0.23

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 97 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_DN, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_CONTAINING_COMPLEX_ASSEMBLY, AAGCAAT_MIR137, GOBP_REGULATION_OF_PROTEIN_POLYMERIZATION, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_POLYMERIZATION, MAZ_Q6, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, TGACCTY_ERR1_Q2, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION, GOBP_REGULATION_OF_ACTIN_FILAMENT_BASED_PROCESS, BILD_HRAS_ONCOGENIC_SIGNATURE, GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_SIZE, GOBP_ACTIN_FILAMENT_ORGANIZATION, ACATTCC_MIR1_MIR206

GO Biological Process (1): negative regulation of actin filament polymerization (GO:0030837)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (4): cytoplasm (GO:0005737), cytosol (GO:0005829), cytoskeleton (GO:0005856), microtubule cytoskeleton (GO:0015630)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
actin filament polymerization	1
regulation of actin filament polymerization	1
negative regulation of protein polymerization	1
negative regulation of cytoskeleton organization	1
negative regulation of supramolecular fiber organization	1
binding	1
intracellular anatomical structure	1
cytoplasm	1
intracellular membraneless organelle	1
cytoskeleton	1

Protein interactions and networks

STRING

1128 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KANK4	AGBL1	Q96MI9	708
KANK4	LOXHD1	Q8IVV2	648
KANK4	SLC4A11	Q8NBS3	570
KANK4	LAMC1	P11047	516
KANK4	KANK2	Q63ZY3	503
KANK4	KANK1	Q14678	488
KANK4	SYNPO	Q8N3V7	484
KANK4	ATP1B1	P05026	468
KANK4	COL8A2	P25067	460
KANK4	CFDP1	Q9UEE9	459
KANK4	PATJ	Q8NI35	449
KANK4	EMP2	P54851	438
KANK4	ARHGAP24	Q8N264	419
KANK4	RHOA	P06749	411
KANK4	INF2	Q27J81	404

IntAct

25 interactions, top by confidence:

A	B	Type	Score
KANK4	TRAPPC3	psi-mi:“MI:0914”(association)	0.640
KANK4	TRAPPC10	psi-mi:“MI:0914”(association)	0.640
KANK4	CUL5	psi-mi:“MI:0915”(physical association)	0.560
KANK4	HOMER3	psi-mi:“MI:0915”(physical association)	0.560
HAT1	KANK4	psi-mi:“MI:0915”(physical association)	0.560
KANK4	MYLIP	psi-mi:“MI:0915”(physical association)	0.560
TRAPPC6A	KANK4	psi-mi:“MI:0915”(physical association)	0.560
CSK	KANK4	psi-mi:“MI:0915”(physical association)	0.560
KANK4	PKM	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
KANK4		psi-mi:“MI:0914”(association)	0.350
NOL8	URB1	psi-mi:“MI:0914”(association)	0.350
CUL5	KANK4	psi-mi:“MI:0915”(physical association)	0.000
HOMER3	KANK4	psi-mi:“MI:0915”(physical association)	0.000
HAT1	KANK4	psi-mi:“MI:0915”(physical association)	0.000
MYLIP	KANK4	psi-mi:“MI:0915”(physical association)	0.000
CSK	KANK4	psi-mi:“MI:0915”(physical association)	0.000
TRAPPC6A	KANK4	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (36): TLN2 (Affinity Capture-MS), TRAPPC9 (Affinity Capture-MS), C7orf43 (Affinity Capture-MS), OSCP1 (Affinity Capture-MS), TLN1 (Affinity Capture-MS), TRAPPC10 (Affinity Capture-MS), TRAPPC4 (Affinity Capture-MS), TRAPPC2 (Affinity Capture-MS), TRAPPC1 (Affinity Capture-MS), TRAPPC3 (Affinity Capture-MS), TRAPPC5 (Affinity Capture-MS), PDCD2L (Affinity Capture-MS), TRIM11 (Affinity Capture-MS), KANK4 (Affinity Capture-RNA), KANK4 (Two-hybrid)

ESM2 similar proteins: A0A0U1RQ45, A0A1B0GWB2, A2A9T0, A6QPA0, A7MCY6, D3ZFB6, E9PUL5, E9Q0B3, F5GYI3, F5H4A9, J3QNX5, O70142, P0C1G7, P81408, P97764, P98077, Q148V8, Q15654, Q2KI80, Q3SX26, Q3SZL6, Q4V9L6, Q5FVJ4, Q5FW56, Q5RAC1, Q5T7N3, Q6DG50, Q6PAJ3, Q6PJ61, Q6ZMQ8, Q6ZNR0, Q6ZRV2, Q75VX8, Q7Z6L0, Q86UK7, Q86VE0, Q8BGW2, Q8BRJ3, Q8BX43, Q8C0R7

Diamond homologs: D3ZD05, E9Q238, Q14678, Q1LZH7, Q5T7N3, Q63ZY3, Q6NY19, Q6P9J5, Q8BX02, Q9Z1P7, X1WE18, P93002, Q68DC2, A2AS55, Q04861, Q499M5, Q641X1, Q9Z2F6, O35516, Q04721, Q337A0, Q61982, Q9QW30, Q9R172, Q9UM47, A0A0R4IQZ2, A6NCL7, A6NGH8, O83515, P0C0T2, P13508, P20749, P53356, Q18297, Q21920, Q3U0L2, Q4FE45, Q4JHE0, Q810B6, Q9CQM6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

419 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	248
Likely benign	88
Benign	55

Top pathogenic / likely-pathogenic (0)

SpliceAI

2454 predictions. Top by Δscore:

Variant	Effect	Δscore
1:62247467:CTCA:C	donor_loss	1.0000
1:62247469:CACCT:C	donor_loss	1.0000
1:62247470:A:C	donor_loss	1.0000
1:62247471:C:CG	donor_loss	1.0000
1:62253062:CCCA:C	donor_loss	1.0000
1:62253064:CA:C	donor_loss	1.0000
1:62253066:CCTGA:C	donor_loss	1.0000
1:62268329:T:A	donor_gain	1.0000
1:62268501:CATAC:C	acceptor_gain	1.0000
1:62268502:ATAC:A	acceptor_gain	1.0000
1:62268503:TAC:T	acceptor_gain	1.0000
1:62268507:T:G	acceptor_loss	1.0000
1:62281548:CCAT:C	donor_gain	1.0000
1:62238497:T:TA	donor_gain	0.9900
1:62247470:A:AC	donor_gain	0.9900
1:62247471:C:CC	donor_gain	0.9900
1:62247668:CCTCC:C	acceptor_gain	0.9900
1:62247669:CTCC:C	acceptor_gain	0.9900
1:62247669:CTCCC:C	acceptor_gain	0.9900
1:62247670:TCCCT:T	acceptor_gain	0.9900
1:62247671:CC:C	acceptor_gain	0.9900
1:62247672:CC:C	acceptor_gain	0.9900
1:62247673:C:CC	acceptor_gain	0.9900
1:62247673:C:G	acceptor_loss	0.9900
1:62247676:CA:C	acceptor_gain	0.9900
1:62247677:A:C	acceptor_gain	0.9900
1:62253207:CGC:C	acceptor_gain	0.9900
1:62253209:CCTGC:C	acceptor_loss	0.9900
1:62253210:C:A	acceptor_loss	0.9900
1:62253210:C:CC	acceptor_gain	0.9900

AlphaMissense

6498 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:62263281:A:G	W784R	0.999
1:62263281:A:T	W784R	0.999
1:62271495:A:C	F665L	0.999
1:62271495:A:T	F665L	0.999
1:62271497:A:G	F665L	0.999
1:62273395:A:G	L570P	0.999
1:62274987:G:C	F39L	0.999
1:62274987:G:T	F39L	0.999
1:62274988:A:C	F39C	0.999
1:62274988:A:G	F39S	0.999
1:62274989:A:G	F39L	0.999
1:62275000:A:G	L35S	0.999
1:62275005:A:C	F33L	0.999
1:62275005:A:T	F33L	0.999
1:62275007:A:G	F33L	0.999
1:62263138:G:C	S831R	0.998
1:62263138:G:T	S831R	0.998
1:62263140:T:G	S831R	0.998
1:62271496:A:G	F665S	0.998
1:62274985:A:G	L40P	0.998
1:62271496:A:C	F665C	0.997
1:62273296:A:G	L603P	0.997
1:62273392:A:G	L571P	0.997
1:62274994:A:G	L37P	0.997
1:62275006:A:G	F33S	0.997
1:62253184:G:C	N855K	0.996
1:62253184:G:T	N855K	0.996
1:62274980:A:G	Y42H	0.996
1:62263151:G:T	A827D	0.995
1:62263279:C:A	W784C	0.995

dbSNP variants (sampled 300 via entrez): RS1000025060 (1:62288305 G>A,T), RS1000088070 (1:62308182 A>T), RS1000095722 (1:62259582 T>G), RS1000308234 (1:62310679 C>A,T), RS1000309367 (1:62275450 A>C), RS1000359700 (1:62245333 T>C), RS1000387759 (1:62262463 A>C), RS1000458800 (1:62288967 C>A), RS1000493792 (1:62262627 A>G), RS1000531269 (1:62259473 C>T), RS1000544028 (1:62254717 C>A,T), RS1000610825 (1:62299067 A>T), RS1000661170 (1:62296799 C>A,T), RS1000698450 (1:62316606 G>T), RS1000718225 (1:62241843 A>G)

Disease associations

OMIM: gene MIM:614612 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
nephrotic syndrome	Moderate	Autosomal recessive

Mondo (1): nephrotic syndrome (MONDO:0005377)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST004217_1	Fuchs’s corneal dystrophy	1.000000e-14
GCST006920_5	Regular attendance at a gym or sports club	1.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0009592	social interaction measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D009404	Nephrotic Syndrome	C12.050.351.968.419.630.643; C12.200.777.419.630.643; C12.950.419.630.643

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	8
Benzo(a)pyrene	affects methylation, decreases expression, decreases methylation	5
Aflatoxin B1	decreases expression, increases methylation	4
trichostatin A	affects cotreatment, increases expression	3
sodium arsenite	increases abundance, increases expression, affects expression	3
Cyclosporine	decreases expression	3
bisphenol A	affects expression, decreases methylation	2
Vorinostat	affects cotreatment, increases expression	2
Panobinostat	increases expression, affects cotreatment	2
Nickel	decreases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Smoke	decreases expression	2
propionaldehyde	decreases expression	1
arsenite	increases methylation	1
butyraldehyde	decreases expression	1
benzo(e)pyrene	decreases methylation	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
Decitabine	affects expression	1
Arsenic Trioxide	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	increases abundance, increases expression	1
Atrazine	increases expression	1
Azathioprine	decreases expression	1
Carbamazepine	affects expression	1
Cisplatin	affects expression	1
Cytarabine	decreases expression	1
Diethylnitrosamine	decreases expression	1
Dimethyl Sulfoxide	increases expression	1

Clinical trials (associated diseases)

104 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00308321	PHASE4	UNKNOWN	Long Term Tapering or Standard Steroids for Nephrotic Syndrome
NCT01021540	PHASE4	COMPLETED	Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes
NCT01028287	PHASE4	COMPLETED	Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)
NCT01162005	PHASE4	COMPLETED	Therapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in Children
NCT01895894	PHASE4	COMPLETED	Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome
NCT02238418	PHASE4	COMPLETED	Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria.
NCT02382575	PHASE4	UNKNOWN	Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistant Nephrotic Syndrome
NCT02427880	PHASE4	COMPLETED	Role of Acetazolamide and Hydrochlorothiazide Followed by Furosemide in Treating Nephrotic Edema
NCT03210688	PHASE4	COMPLETED	Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy
NCT03347357	PHASE4	COMPLETED	Pharmacokinetics of Tacrolimus in Children
NCT05696977	PHASE4	UNKNOWN	Effect of Obesity on Cyclosporine Blood Trough Level in Nephrotic Syndrome Patients
NCT05966818	PHASE4	UNKNOWN	Effect of Dapagliflozin in Non-Diabetic Patients With Nephrotic Syndrome.
NCT06026787	PHASE4	COMPLETED	Clinical Value of Adding Dapagliflozin in Patients With Nephrotic Syndrome
NCT00354731	PHASE3	COMPLETED	Efficacy of Pentoxifylline on Primary Nephrotic Syndrome
NCT00615667	PHASE3	COMPLETED	Prospective, Multicenter Study of the Efficacy and Tolerance of Tacrolimus on Refractory Nephrotic Syndrome (RNS)
NCT00981838	PHASE3	COMPLETED	Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS)
NCT01197040	PHASE3	COMPLETED	Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome
NCT01309477	PHASE3	COMPLETED	The Efficacy and Tolerance of Tacrolimus Sustained-release Capsules on Refractory Nephrotic Syndrome (RNS)
NCT02132195	PHASE3	COMPLETED	Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome
NCT02257697	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome
NCT02438982	PHASE3	COMPLETED	Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome
NCT03141970	PHASE3	COMPLETED	Prednisolone Trial in Children Younger Than 4 Years
NCT03501459	PHASE3	UNKNOWN	Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic Syndrome
NCT05079789	PHASE3	TERMINATED	Amiloride in Nephrotic Syndrome
NCT05716880	PHASE3	RECRUITING	Ketoanalogues for Muscle Mass Loss in Nephrotic Syndrome
NCT06635720	PHASE3	ACTIVE_NOT_RECRUITING	REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE)
NCT00001212	PHASE2	COMPLETED	Drug Therapy in Lupus Nephropathy
NCT00001959	PHASE2	COMPLETED	Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)
NCT00004466	PHASE2	TERMINATED	Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome
NCT00004990	PHASE2	COMPLETED	Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis
NCT00977977	PHASE2	RECRUITING	Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
NCT02394106	PHASE2	TERMINATED	Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic Syndrome
NCT02394119	PHASE2	COMPLETED	Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome
NCT02592798	PHASE2	COMPLETED	Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
NCT02966717	PHASE2	UNKNOWN	Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)
NCT03004001	PHASE2	TERMINATED	Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome
NCT03949855	PHASE2	RECRUITING	Belimumab With Rituximab for Primary Membranous Nephropathy
NCT05599815	PHASE2	WITHDRAWN	Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome
NCT05704400	PHASE2	UNKNOWN	Efficacy of Anti-CD20 Ab Associated With Anti-CD38 in the Childhood Multidrug Dependent and Resistant Nephrotic Syndrome
NCT06983028	PHASE2	RECRUITING	Atacicept in Multiple Glomerular Diseases